{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:54:43Z","timestamp":1791813283415,"version":"4.3.4"},"reference-count":120,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.autrev.2020.102731","type":"journal-article","created":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T02:49:43Z","timestamp":1608000583000},"page":"102731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment"],"prefix":"10.1016","volume":"20","author":[{"given":"Mads","family":"Br\u00fcner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Dige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Gitte","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine Bay","family":"Laurberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen Steen","family":"Agnholt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e5re","family":"Clemmensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Lories","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasper Fjellhaugen","family":"Hjuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tue Wenzel","family":"Kragstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2020.102731_bb0005","series-title":"Immune-mediated inflammatory diseases: progress in molecular pathogenesis and therapeutic strategies","first-page":"297","volume":"9","author":"Bayry","year":"2013"},{"key":"10.1016\/j.autrev.2020.102731_bb0010","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/ibd.20406","article-title":"Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002","volume":"14","author":"Cohen","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2020.102731_bb0015","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamadermatol.2018.3631","article-title":"Association of Psoriasis with Inflammatory Bowel Disease","volume":"154","author":"Fu","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10067-018-4332-7","article-title":"Role of comorbidities in spondyloarthritis including psoriatic arthritis","volume":"38","author":"Scriffignano","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0025","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s10067-015-2960-8","article-title":"Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease","volume":"34","author":"Rosenbaum","year":"2015","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s11926-018-0785-6","article-title":"Bridging the gaps in the Care of Psoriasis and Psoriatic Arthritis: the role of combined clinics","volume":"20","author":"Haberman","year":"2018","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2020.102731_bb0035","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102731_bb0040","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res"},{"issue":"5","key":"10.1016\/j.autrev.2020.102731_bb0045","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102731_bb0050","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1111\/jdv.14454","article-title":"European S3-guideline on the systemic treatment of psoriasis vulgaris - update Apremilast and Secukinumab - EDF in cooperation with EADV and IPC","volume":"31","author":"Nast","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2020.102731_bb0055","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0060","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO guidelines on therapeutics in Crohn's Disease: medical treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.autrev.2020.102731_bb0065","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2020.102731_bb0070","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0075","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0080","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0085","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0090","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/acr.22848","article-title":"Observed incidence of uveitis following Certolizumab Pegol treatment in patients with axial Spondyloarthritis","volume":"68","author":"Rudwaleit","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2020.102731_bb0095","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0100","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0105","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","article-title":"Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, part 1","volume":"73","author":"Sieper","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102731_bb0110","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/ard.2004.025882","article-title":"Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors","volume":"64","author":"Bodaghi","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102731_bb0115","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0120","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0125","series-title":"Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study","first-page":"976","volume":"60","author":"Kavanaugh","year":"2009"},{"key":"10.1016\/j.autrev.2020.102731_bb0130","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3899\/jrheum.180312","article-title":"Reduced occurrence rate of acute anterior uveitis in Ankylosing spondylitis treated with Golimumab \u2014 the GO-EASY study","volume":"46","author":"Van Bentum","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0135","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0140","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0145","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/archopht.121.4.437","article-title":"Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate","volume":"121","author":"Foster","year":"2003","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.autrev.2020.102731_bb0150","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/ard.2006.052092","article-title":"Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study","volume":"65","author":"Guignard","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102731_bb0155","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaad.2011.07.034","article-title":"Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept","volume":"67","author":"Bagel","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0160","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1111\/bjd.12060","article-title":"A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis","volume":"168","author":"Ortonne","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0165","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-016-0564-5","article-title":"Nail psoriasis: a review of treatment options","volume":"76","author":"Pasch","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2020.102731_bb0170","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2020.102731_bb0175","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0180","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0185","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0190","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2020.102731_bb0195","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0200","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0205","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0210","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0215","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102731_bb0220","series-title":"Editor (Ed.)^(Eds.), Book OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial, BMJ Publishing Group Ltd and European League Against Rheumatism","article-title":"OP0307 Efficacy and safety of risankizumab, a selective il-23p19 inhibitor, in patients with active psoriatic arthritis over 24 weeks: results from a phase 2 trial","author":"Mease","year":"2020"},{"key":"10.1016\/j.autrev.2020.102731_bb0225","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1016\/S0140-6736(17)30570-6","article-title":"Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study","volume":"389","author":"Feagan","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102731_bb0230","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0235","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0240","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0245","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0250","series-title":"OP0235 Secukinumab improves axial manifestations in patients with psoriatic arthritis and inadequate response to NSAIDs: Primary analysis of the MAXIMISE trial","author":"Baraliakos","year":"2019"},{"key":"10.1016\/j.autrev.2020.102731_bb0255","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","article-title":"Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials","volume":"120","author":"Dick","year":"2013","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2020.102731_bb0260","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ophtha.2014.12.033","article-title":"Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy","volume":"122","author":"Letko","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2020.102731_bb0265","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2020.102731_bb0270","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0275","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0280","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bjd.16736","article-title":"Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis","volume":"179","author":"Ryan","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0285","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0290","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0295","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-eular.6888","article-title":"OP0234 Efficacy and safety of brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in patients with axial spondyloarthritis: A 16 week results of a phase 3, multicenter, randomized, double-blind, placebo-controlled study","author":"Wei","year":"2019"},{"key":"10.1016\/j.autrev.2020.102731_bb0300","article-title":"Brodalumab in psoriatic arthritis (PsA): 24-week results from the phase III AMVISON-1 and -2 trials","volume":"81","author":"Mcinnes","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0305","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102731_bb0310","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of Brodalumab in patients with moderate-to-severe Crohn\u2019s disease","volume":"111","author":"Targan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.autrev.2020.102731_bb0315","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0320","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0325","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102731_bb0330","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/ard.2010.145946","article-title":"Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102731_bb0335","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.gastro.2012.04.010","article-title":"Abatacept for Crohn's disease and ulcerative colitis","volume":"143","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2020.102731_bb0340","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0345","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0350","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/ecco-jcc\/jjy019","article-title":"Efficacy of Vedolizumab in fistulising Crohn\u2019s disease: exploratory analyses of data from GEMINI 2","volume":"12","author":"Feagan","year":"2018","journal-title":"J Crohn\u2019s Colitis"},{"key":"10.1016\/j.autrev.2020.102731_bb0355","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2016-210233","article-title":"An induction or flare of arthritis and\/or sacroiliitis by vedolizumab in inflammatory bowel disease: a case series","volume":"76","author":"Varkas","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102731_bb0360","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jbspin.2017.01.012","article-title":"Arthritis occurrence or reactivation under Vedolizumab treatment for inflammatory bowel disease. A four cases report","volume":"85","author":"Wendling","year":"2018","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2020.102731_bb0365","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10067-018-4357-y","article-title":"Letter to editor: new onset\/recurrence of inflammatory arthralgia\/spondyloarthritis in patients treated with vedolizumab for intestinal bowel disease","volume":"38","author":"Tamanini","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0370","series-title":"Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease","author":"Orlando","year":"2017"},{"key":"10.1016\/j.autrev.2020.102731_bb0375","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0380","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0385","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1136\/annrheumdis-2012-201915","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis","volume":"72","author":"Pathan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102731_bb0390","author":"European Medicines Agency"},{"key":"10.1016\/j.autrev.2020.102731_bb0395","author":"U.S. Food & Drug Administration"},{"key":"10.1016\/j.autrev.2020.102731_bb0400","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"Van Der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2020.102731_bb0405","series-title":"Tofacitinib, an ORAL JANUS KINASE INHIBITOR, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, Phase III trials","first-page":"949","volume":"173","author":"Papp","year":"2015"},{"key":"10.1016\/j.autrev.2020.102731_bb0410","series-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","first-page":"552","volume":"386","author":"Bachelez","year":"2015"},{"key":"10.1016\/j.autrev.2020.102731_bb0415","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0420","series-title":"Editor (Ed.)^(Eds.), Book sammenh\u00e6ngende patientforl\u00f8b - hvad oplever patienter med autoimmune kroniske lidelser?","article-title":"Sammenh\u00e6ngende patientforl\u00f8b - hvad oplever patienter med autoimmune kroniske lidelser?","author":"Jansb\u00f8l","year":"2014"},{"key":"10.1016\/j.autrev.2020.102731_bb0425","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/1744666X.2018.1524755","article-title":"Golimumab in the treatment of psoriatic arthritis","volume":"14","author":"Love","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2020.102731_bb0430","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nrrheum.2015.169","article-title":"TNF biology, pathogenic mechanisms and emerging therapeutic strategies","volume":"12","author":"Kalliolias","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0435","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.rdc.2015.07.010","article-title":"Biologic therapy for psoriatic arthritis","volume":"41","author":"Mease","year":"2015","journal-title":"Rheum Dis Clin North Am"},{"key":"10.1016\/j.autrev.2020.102731_bb0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jval.2017.05.025","article-title":"Comparison of Adalimumab and Etanercept for the treatment of moderate to severe psoriasis: an indirect comparison using individual patient data from randomized trials","volume":"21","author":"Papp","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.autrev.2020.102731_bb0445","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","article-title":"Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease","volume":"124","author":"Van den Brande","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2020.102731_bb0450","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/gut.50.2.206","article-title":"Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn\u2019s disease","volume":"50","author":"ten Hove","year":"2002","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2020.102731_bb0455","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1053\/j.gastro.2011.08.032","article-title":"Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14(+) macrophages","volume":"141","author":"Atreya","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2020.102731_bb0460","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.gastro.2004.11.060","article-title":"Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha","volume":"128","author":"Mitoma","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2020.102731_bb0465","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2020.102731_bb0470","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102731_bb0475","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1111\/jdv.14433","article-title":"The role of IL-23 and the IL-23\/TH 17 immune axis in the pathogenesis and treatment of psoriasis","volume":"31","author":"Girolomoni","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2020.102731_bb0480","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of Ustekinumab and Etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102731_bb0485","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, p","volume":"76","author":"Reich","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0490","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","article-title":"Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102731_bb0495","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials","volume":"390","author":"Reich","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102731_bb0500","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial Spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102731_bb0505","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/09546634.2018.1527994","article-title":"Treatment of psoriatic arthritis with secukinumab: a case series","volume":"29","author":"Nicola","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.autrev.2020.102731_bb0510","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/psb.1771","article-title":"Ixekizumab: targeting plaque psoriasis and psoriatic arthritis","volume":"30","author":"Chaplin","year":"2019","journal-title":"Prescriber"},{"key":"10.1016\/j.autrev.2020.102731_bb0515","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3899\/jrheum.150182","article-title":"Improvement in psoriasis signs and symptoms assessed by the psoriasis symptom inventory with Brodalumab treatment in patients with psoriatic arthritis","volume":"43","author":"Mease","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0520","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102731_bb0525","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102731_bb0530","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2014 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102731_bb0535","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study","volume":"177","author":"Reich","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0540","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102731_bb0545","series-title":"Editor (Ed.)^(Eds.), Book New Head-to-Head Phase 3 data Show Skyrizi\u2122 (risankizumab) Superior to Cosentyx\u00ae* (secukinumab) across primary and all ranked secondary endpoints in adults with moderate to severe plaque psoriasis at 52 weeks","article-title":"New Head-to-Head Phase 3 data show Skyrizi\u2122 (risankizumab) superior to Cosentyx\u00ae* (secukinumab) Across primary and all ranked secondary endpoints in adults with moderate to severe plaque psoriasis at 52 weeks","author":"Abbvie","year":"2020"},{"issue":"6","key":"10.1016\/j.autrev.2020.102731_bb0550","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial","volume":"182","author":"Blauvelt","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2020.102731_bb0555","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102731_bb0560","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2020.102731_bb0565","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of Ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2020.102731_bb0570","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/1744666X.2018.1527218","article-title":"Abatacept for the treatment of psoriatic arthritis","volume":"14","author":"Lubrano","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.autrev.2020.102731_bb0575","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40487-019-0096-8","article-title":"A review of immune-mediated adverse events in melanoma","volume":"7","author":"Kennedy","year":"2019","journal-title":"Oncol Therapy"},{"key":"10.1016\/j.autrev.2020.102731_bb0580","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s40265-015-0439-1","article-title":"Apremilast: a review in psoriasis and psoriatic arthritis","volume":"75","author":"Deeks","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.autrev.2020.102731_bb0585","article-title":"IL-12\/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis","volume":"11","author":"Kragstrup","year":"2019","journal-title":"Therapeutic Adv Musculoskeletal Dis"},{"key":"10.1016\/j.autrev.2020.102731_bb0590","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tem.2017.11.001","article-title":"JAK\/STAT \u2013 emerging players in metabolism","volume":"29","author":"Dodington","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.autrev.2020.102731_bb0595","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.02226","article-title":"The IL-20 cytokine family in rheumatoid arthritis and spondyloarthritis","volume":"9","author":"Kragstrup","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2020.102731_bb0600","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220303128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997220303128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:19:34Z","timestamp":1761599974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997220303128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":120,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1568997220303128"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102731","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2020.102731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102731"}}